Wells Fargo names 13 stocks as overweight tactical ideas
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall St set for lower open as AI jitters rekindle, oil gains
- Brent hits five-month high on escalating Middle East conflict
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- JPMorgan says AI stock selling may be nearing its limit as positioning resets
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
Citi Opens 90-Day Upside Catalyst Watch on Kymera Therapeutics (KYMR)
October 5, 2026 5:24 AM EDTCiti analyst Geoff Meacham reiterated a Buy rating and $150.00 price target on Kymera Therapeutics (NASDAQ: KYMR)
Opens 90-Day Upside Catalyst Watch.For an analyst ratings summary and ratings history on Kymera Therapeutics click here. For more ratings news on Kymera Therapeutics click here.
Shares of Kymera Therapeutics closed at $107.39 yesterday.
... More


